Latest news with #StephanGratziani
Yahoo
a day ago
- Business
- Yahoo
Herbalife CEO and CFO to Participate in Barclays Global Consumer Staples Conference on September 2
LOS ANGELES, August 19, 2025--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced Stephan Gratziani, Chief Executive Officer, and John DeSimone, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 at 4:30 p.m. ET (1:30 p.m. PT). A link to the live webcast will be available under the Investor Relations section of Herbalife's website at A replay of the webcast will also be available at the same website following the completion of the event and for six months thereafter. About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit View source version on Contacts Media Contact: Thien HoVice President, Global Corporate Communicationsthienh@ Investor Contact: Erin BanyasVice President, Head of Investor Relationserinba@ Sign in to access your portfolio
Business Wire
a day ago
- Business
- Business Wire
Herbalife CEO and CFO to Participate in Barclays Global Consumer Staples Conference on September 2
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced Stephan Gratziani, Chief Executive Officer, and John DeSimone, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 at 4:30 p.m. ET (1:30 p.m. PT). A link to the live webcast will be available under the Investor Relations section of Herbalife's website at A replay of the webcast will also be available at the same website following the completion of the event and for six months thereafter. About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit
Yahoo
14-05-2025
- Business
- Yahoo
HLF Q1 Earnings Call: Herbalife Outlines Tech Transformation Amid Revenue Miss
Health and wellness products company Herbalife (NYSE:HLF) missed Wall Street's revenue expectations in Q1 CY2025, with sales falling 3.4% year on year to $1.22 billion. On the other hand, the company expects next quarter's revenue to be around $1.26 billion, close to analysts' estimates. Its non-GAAP profit of $0.59 per share was 43.9% above analysts' consensus estimates. Is now the time to buy HLF? Find out in our full research report (it's free). Revenue: $1.22 billion vs analyst estimates of $1.23 billion (3.4% year-on-year decline, 0.5% miss) Adjusted EPS: $0.59 vs analyst estimates of $0.41 (43.9% beat) Adjusted EBITDA: $164.9 million vs analyst estimates of $147.2 million (13.5% margin, 12% beat) Revenue Guidance for Q2 CY2025 is $1.26 billion at the midpoint, roughly in line with what analysts were expecting EBITDA guidance for the full year is $640 million at the midpoint, above analyst estimates of $633.6 million Operating Margin: 10.1%, up from 5.7% in the same quarter last year Free Cash Flow was -$18.1 million compared to -$19.1 million in the same quarter last year Organic Revenue rose 1.4% year on year (2.4% in the same quarter last year) Market Capitalization: $693.6 million Herbalife's first quarter results reflected ongoing transformation efforts, as management highlighted the company's shift toward technology-driven personalization and new product offerings. President and incoming CEO Stephan Gratziani emphasized recent acquisitions—especially the launch of the Pro2col digital platform and Link BioSciences' personalized supplement manufacturing—as foundational to Herbalife's strategy. Management attributed Q1's results primarily to cost-saving initiatives and continued distributor engagement, noting, 'Our new distributor growth was up 16% year over year, marking the fourth consecutive quarter of growth.' Looking ahead, Herbalife's forward guidance is shaped by investments in digital platforms, expanded product portfolios, and a focus on operational efficiency. CFO John DeSimone explained that while macroeconomic and foreign exchange headwinds persist, cost controls and the expected rollout of Pro2col should support margin improvement and incremental growth. Management remains cautious on China, with DeSimone stating, 'We're going to wait and see on China before we roll any meaningful upside into our projections.' Herbalife's management underscored several strategic initiatives and market dynamics behind the quarter's financial performance, with a focus on technology integration and distributor engagement. Deviations from Wall Street expectations were mainly due to foreign exchange headwinds and mixed regional volume trends. Acquisitions and Platform Launch: Management completed acquisitions of Pro2col (a digital health platform), Pruvit (ketone supplement IP), and Link BioSciences (personalized supplement manufacturing). The Pro2col platform aims to integrate AI-driven nutrition tracking and personalized health recommendations for distributors and customers. Distributor Engagement Initiatives: Herbalife reported a 16% year-over-year increase in new distributors, attributing this to enhanced training programs and engagement events like the Flex45 Challenge and regional Extravaganzas. Regional Performance Variability: While Latin America, EMEA (Europe, Middle East, and Africa), and Asia Pacific saw local currency sales growth, reported revenues were constrained by currency headwinds. North America experienced lower volumes, partly offset by price increases, while China faced a 14% volume decline. Cost Savings and Margin Expansion: Adjusted EBITDA margin improved due to pricing actions and reduced raw material costs, as well as restructuring and operational efficiency measures taken in 2024. Product Portfolio Diversification: Management highlighted the rollout of new product categories, particularly through Pruvit's ketone supplements and future Pro2col-branded offerings, as key to expanding Herbalife's customer base and increasing engagement. Management's outlook for the coming quarters centers on leveraging digital health platforms, expanding the product portfolio, and sustaining operational efficiency, while remaining mindful of macroeconomic risks and regional market uncertainties. Digital Platform Expansion: The upcoming launch of the Pro2col digital health platform is expected to drive incremental product sales, deepen customer engagement, and enhance distributor recruitment, though management noted revenue contribution will be limited in early phases. Personalization and Premium Offerings: The integration of Link BioSciences' personalized supplement technology targets a more sophisticated customer segment, including athletes, and is expected to differentiate Herbalife in mature markets over time. Regional Growth Strategy: Management projects continued distributor growth and local currency momentum outside China, but remains cautious on China's recovery and anticipates ongoing foreign exchange volatility as a headwind to reported results. Chasen Bender (Citi): Asked about the monetization strategy and ROI for the Pro2col platform; management replied that while early-stage, revenue streams will include app fees, incremental product sales, and new distributor acquisition, with more detailed modeling expected after commercial launch. Chasen Bender (Citi): Inquired about weaker distributor and volume trends in North America; management attributed this to temporary disruptions from technology launches and expects sequential improvement through the year. John Baumgartner (Mizuho Securities): Questioned the target audience for Link BioSciences; CEO Gratziani explained it will initially serve premium customers and athletes, but expects broader adoption of personalized nutrition over time. Rob Rigby (Bank of America): Asked about tariff impacts and sourcing from China; CFO DeSimone stated tariffs will have a limited financial effect due to U.S.-based manufacturing and duty drawbacks. Doug Lane (Water Tower Research): Queried on capital spending for Pro2col and overall CapEx; management clarified that spending is reprioritized from other projects and fully included in updated guidance, with no permanent elevation in capital expenditures anticipated. In the upcoming quarters, the StockStory team will monitor (1) the rollout and adoption rates of the Pro2col digital platform in the U.S. and subsequent markets, (2) improvements in North American distributor activity and volume trends following recent technology integrations, and (3) signs of stabilization or recovery in China's sales volumes. Progress on personalized supplement offerings and the effectiveness of engagement initiatives like the Flex45 Challenge will also be important indicators of execution. Herbalife currently trades at a forward P/E ratio of 3.3×. Should you load up, cash out, or stay put? See for yourself in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-05-2025
- Business
- Yahoo
Why Herbalife (HLF) Stock Is Down Today
Shares of health and wellness products company Herbalife (NYSE:HLF) fell 8.5% in the afternoon session after the company reported weak first quarter 2025 results which included EBITDA guidance for next quarter that missed and organic revenue that fell short of Wall Street's estimates. Sales declined 3.4% year over year, but when adjusting for currency impacts, sales rose a modest 1.4%, with strength in Latin America and EMEA offset by steep declines in China and a pullback in North America. On the other hand, Herbalife beat analysts' EBITDA and EPS expectations. Overall, this quarter was mixed yet weaker. The shares closed the day at $6.63, down 7.7% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Herbalife? Access our full analysis report here, it's free. Herbalife's shares are extremely volatile and have had 33 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock gained 44.6% on the news that the company reported impressive fourth-quarter results, which blew past analysts' EPS and EBITDA estimates. On the other hand, revenue guidance for the next quarter missed expectations, with sales projected to decline between 5.5% and 1.5% y/y. Full-year EBITDA guidance also fell short of Wall Street's estimates, raising concerns about the company's ability to sustain its margins and profits. Overall, this was a solid quarter. Separately, the company announced that Stephan Gratziani is stepping into the CEO's chair, replacing Michael Johnson, who will transition to the role of Executive Chairman. Herbalife is down 0.7% since the beginning of the year, and at $6.63 per share, it is trading 46.9% below its 52-week high of $12.49 from July 2024. Investors who bought $1,000 worth of Herbalife's shares 5 years ago would now be looking at an investment worth $190.08. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
12-03-2025
- Business
- Yahoo
Herbalife to Acquire Assets of Pro2col Health and Pruvit Ventures, and Controlling Ownership Interest in Link BioSciences
Accelerates Journey to Become the World's Premier Health and Wellness Platform LOS ANGELES, March 12, 2025--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced it has entered into a binding memorandum of understanding to acquire 100% of the assets of Pro2col Health LLC (Pro2col) and Pruvit Ventures, Inc. (Pruvit), as well as a 51% controlling ownership interest in Link BioSciences Inc. (Link BioSciences). Pro2col is a health and wellness digital application company, which will use individual biometrics to provide personalized nutrition recommendations in support of a healthy, active lifestyle. The platform is designed to deliver tailored health and longevity protocols. Link BioSciences is an established manufacturing company that utilizes proprietary technology to process biometrics, biomarkers, lifestyle data, and DNA, and will harness the information from Pro2col to formulate personalized nutritional supplements for customers. "By acquiring and leveraging Pro2col's personalized digital technology, along with Link BioSciences' manufacturing capabilities, Herbalife will be providing our expansive network of distributors with unique opportunities to expand their customer base through a personalized health, wellness and nutrition platform," said Stephan Gratziani, Herbalife President and incoming CEO. "These investments further accelerate our vision to modernize our business and represent a belief in our business model that better positions us to become the world's premier health and wellness company, community and platform." A beta version of the Pro2col technology platform is expected to be available to select Herbalife independent distributors in the U.S. during the third quarter of 2025. A full release in the U.S. is planned for the fourth quarter of 2025, with additional markets to follow beginning in 2026. Pruvit is a direct-selling market leader of patented ketone supplements. This acquisition expands Herbalife's health and wellness offerings with an attractive, channel-exclusive, new product category. Pruvit will continue to operate independently under its current ownership for up to two years. During this transition period, Herbalife can launch ketone products as the companies come together to bring the Pro2col platform and vision to the world. The transactions are expected to close in the second quarter of 2025 and will cost approximately $25 million to $30 million, with additional conditional payments possible based on future performance. Additionally, Herbalife is deepening its relationship with global soccer legend and long-time Herbalife partner, Cristiano Ronaldo. His years of dedication and focus on nutrition and athletic performance makes him the ideal advisor to support the further development of the Pro2col platform. "As a partner for over a decade, I'm excited to be part of Herbalife's next era," said Cristiano Ronaldo. "This expanded partnership reflects our shared commitment to offering the highest level of nutrition and wellness solutions to the world." "For 45 years, Herbalife has been committed to providing science-backed health and wellness products and a successful business opportunity," said Mr. Gratziani. "We're excited about these acquisitions and partnership with Cristiano Ronaldo, which will propel Herbalife into its next chapter of growth." About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit About Pro2col Health LLC, Pruvit Ventures, Inc. and Link BioSciences Inc. Pro2col is a health and wellness digital application company, which will use individual biometrics to provide personalized nutrition recommendations in support of a healthy, active lifestyle. The platform is designed to deliver tailored health and longevity protocols. Pruvit is a direct-selling market leader of patented ketone supplements with approximately 19,000 active independent distributors, and 100 SKUs in 37 countries. For more information, visit Link BioSciences is an established manufacturing company that utilizes proprietary technology to process biometrics, biomarkers, lifestyle data, and DNA. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management, including for future operations, capital expenditures, or share repurchases; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; any statements of belief or expectation; and any statements of assumptions underlying any of the foregoing or other future events. Forward-looking statements may include, among others, the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "anticipate" or any other similar words. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results or outcomes could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, many of which are beyond our control. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include the following: the potential impacts of current global economic conditions, including inflation, unfavorable foreign exchange rate fluctuations, and tariffs or retaliatory tariffs, on us; our Members, customers, and supply chain; and the world economy; our ability to attract and retain Members; our relationship with, and our ability to influence the actions of, our Members; our noncompliance with, or improper action by our employees or Members in violation of, applicable U.S. and foreign laws, rules, and regulations; adverse publicity associated with our Company or the direct-selling industry, including our ability to comfort the marketplace and regulators regarding our compliance with applicable laws; changing consumer preferences and demands and evolving industry standards, including with respect to climate change, sustainability, and other environmental, social, and governance matters; the competitive nature of our business and industry; legal and regulatory matters, including regulatory actions concerning, or legal challenges to, our products or network marketing program and product liability claims; the Consent Order entered into with the Federal Trade Commission, or FTC, the effects thereof and any failure to comply therewith; risks associated with operating internationally and in China; our ability to execute our growth and other strategic initiatives, including implementation of our restructuring initiatives, and increased penetration of our existing markets; any material disruption to our business caused by natural disasters, other catastrophic events, acts of war or terrorism, including the war in Ukraine, cybersecurity incidents, pandemics, and/or other acts by third parties; our ability to adequately source ingredients, packaging materials, and other raw materials and manufacture and distribute our products; our reliance on our information technology infrastructure; noncompliance by us or our Members with any privacy laws, rules, or regulations or any security breach involving the misappropriation, loss, or other unauthorized use or disclosure of confidential information; contractual limitations on our ability to expand or change our direct-selling business model; the sufficiency of our trademarks and other intellectual property; product concentration; our reliance upon, or the loss or departure of any member of, our senior management team; restrictions imposed by covenants in the agreements governing our indebtedness; risks related to our convertible notes; changes in, and uncertainties relating to, the application of transfer pricing, income tax, customs duties, value added taxes, and other tax laws, treaties, and regulations, or their interpretation; our incorporation under the laws of the Cayman Islands; and share price volatility related to, among other things, speculative trading and certain traders shorting our common shares. Additional factors and uncertainties that could cause actual results or outcomes to differ materially from our forward-looking statements are set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on February 19, 2025, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in our Consolidated Financial Statements and the related Notes included therein. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. Forward-looking statements made in this release speak only as of the date hereof. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. View source version on Contacts Media Contact: Thien HoVice President, Global Corporate Communicationsthienh@ Investor Contact: Erin BanyasVice President, Head of Investor Relationserinba@ Sign in to access your portfolio
